3 November, 2009: The European Commission and the US Food and Drug Administration (FDA) have granted Noscira, a biotechnology subsidiary of Grupo Zeltia (ZEL.MC), orphan drug status for Nypta® (NP-12) for treating Progressive Supranuclear Palsy (PSP), a neurodegenerative disease......
...Nypta® inhibits the GSK-3 enzyme; this is an innovative approach for treating neurodegenerative diseases such as Alzheimer's and PSP. Nypta® is the only GSK-3 inhibitor under clinical development and the only compound capable of acting on all of the histopathological lesions associated with the disease.
From 2006 to 2008, Nypta® was administered to more than 150 healthy volunteers, both young and old, in three double-blind Phase I trials. The first Phase II trial for Alzheimer's was approved in the last quarter of 2008; 30 patients have already been treated, and the results are being processed... Noscira's Press Release -
